Figure 2:

A – Qualifying Sarnat Exam (qSE) and association with primary outcome. Only neonates with moderate or severe encephalopathy were included. In the moderate group, n=209 (58%) experienced disability-free survival, n=47 (13%) mild NDI, n=58 (16%) moderate NDI, n=35 (10%) severe NDI, and n=9 (3%) died. In the severe group, n=27 (27%) experienced disability-free survival, n=9 (9%) mild NDI, n=11 (11%) moderate NDI, n=19 (19%) severe NDI, and n=36 (35%) died. B - Sarnat Exam after rewarming (rSE) and association with primary outcome. In the normal group, n=70 (73%) experienced disability-free survival, n=5 (5%) mild NDI, n=19 (20%) moderate NDI, n=2 (2%) severe NDI, and n=0 (0%) died. In the mild group, n=135 (62%) experienced disability-free survival, n=38 (17%) mild NDI, n=27 (12%) moderate NDI, n=17 (8%) severe NDI , and n=1 (0%) died. In the moderate group, n=28 (30%) experienced disability-free survival, n=9 (10%) mild NDI, n=20 (22%) moderate NDI, n=25 (27%) severe NDI, and n=11 (12%) died. In the severe group, n=3 (6%) experienced disability-free survival, n=4 (8%) mild NDI, n=3 (6%) moderate NDI, n=10 (19%) severe NDI, and n=33 (62%) died. aORs with 95% CI for the HEAL primary outcome (death/NDI) are shown above the plot for each group compared to infants with a moderate (A, qSE) or normal (rSE, B) Sarnat exam. Bolded values display when the 95% CIs do not cross 1. Models are adjusted for sedative medications prior to assessment and ECMO. NDI = Neurodevelopmental Impairment; ECMO = Extracorporeal Membrane Oxygenation.